(8-090) Once-daily Crisaborole as Long-term Maintenance Treatment to Reduce the Incidence of Flares in Patients with Mild-to-moderate Atopic Dermatitis: A 52-week Clinical Trial

Tuesday, December 6, 2022

2:00 PM – 3:30 PM

Location: Bayside A, Level 1

Category: Evaluative Study
Topic: Clinical Topics/Therapeutics

Co-Author(s): Chuanbo Zang, Richard Gower, Maryam Shayesteh Alam, Lawrence Eichenfield

Primary Author(s)

John L. Werth, PhD
Senior Director, Global Product Development
Pfizer, Inc, Pennsylvania